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Introduction
Surgery remains the only potentially curative treatment for 
early-stage non-small cell lung cancer patients (NSCLC) 
resulting in 5-year survival rates ranging from 77% in 
pathological stage IA to 23% in stage IIIA tumors (1).
Clinical trials and meta-analyses have demonstrated that 
in patients with early-stage NSCLC adjuvant chemotherapy 
improves survival (2-6) with an average benefit of 5% 
at 5 years and, consequently, adjuvant chemotherapy 
is recommended for patients with resected stage II-III 
NSCLC (7-9). Nevertheless, a proportion of stage I 
patients have poor prognosis and may benefit significantly 
from adjuvant chemotherapy, while some relatively good 
prognosis stage II patients may not share similar benefits. 
Therefore, new diagnostic paradigms are urgently needed 
to select stage I-II subjects who may take advantage from 
adjuvant chemotherapy and clinical trials.
The strongest clinical prognostic factors in NSCLC 
include stage, sex, age, and performance status (10-12), but 
a better individualization of treatment approaches requires 
a more precise understanding of the molecular features of 
lung cancer.
A wide array of individual molecular markers have 
been tested in advanced as well as early stage NSCLC for 
prognostic and predictive value and this review will focus on 
the current existing evidence to support their investigational 
value. Most of these molecular markers have been found 
to be either prognostic and/or predictive at the same time. 
One of the first and largest retrospective biomarker studies 
in 515 resected stage I NSCLC patients failed to show any 
significant association between survival and the expression 
of an extensive panel of biomarkers, including epidermal 
growth factor receptor (EGFR), HER2/neu, bcl-2, p53 and 
angiogenesis markers (13).
Lastly, the human genome project,  allowed the 
development and clinical applications of genomic-based 
assays, including increasingly dense microarray platforms 
for global analyses of gene expression, copy number 
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variation, DNA methylation and microRNA and several 
genomic signatures have been identified and tested in early 
stage NSCLC for their prognostic value.
Excision repair cross-complementation group 1
Cisplatin inhibits replication by binding to DNA and 
forming platinum-DNA adducts causing strand breaks when 
the DNA helices unwind in preparation for replication. 
The nuclear excision repair (NER) family of genes is 
involved in repair of these DNA strand breaks (14). The 
excision repair cross-complementation group 1 (ERCC1) 
enzyme is involved in the final step of the NER pathway 
that recognizes and removes cisplatin-induced DNA 
adducts, therefore, leading to cisplatin resistance. High 
tumoral ERCC1 expression, therefore, predicts for cisplatin 
resistance.
ERCC1 activity may be assessed as protein by standard 
immunohistochemistry (IHC) or automated AQUA 
technology (15). Alternatively, it can be assessed at the 
mRNA level through quantitative real-time polymerase chain 
reaction (qRT-PCR). Currently, there is no consensus about 
the superiority of one approach versus the other because 
both techniques are rarely assessed concomitantly (16,17).
In resected NSCLC, patients with high ERCC1 
expression (>50 unitless ratio) had a better survival outcome 
(median OS, 94.6 vs. 35.5 months; P=0.01) when compared 
to patients with low ERCC1 expression generating the 
hypothesis that an intact DNA repair mechanism may 
reduce the accumulation of genetic aberrations that are 
thought to contribute to malignant potential phenotype and 
therefore the risk of relapse after definitive treatment (18).
The predictive role of ERCC1 was initially assessed 
by RT-PCR in a series of small retrospective studies in 
advanced NSCLC (19,20). The median overall survival 
(OS) was significantly longer in patients with low ERCC1 
compared to patients with high ERCC1. Subsequently, 
ERCC1 was investigated in a subgroup of patients enrolled 
in a large adjuvant chemotherapy trial (21) and, by standard 
immunohistochemistry, in 761 paraffin-embedded tumor 
samples (22). A benefit from cisplatin-based adjuvant 
chemotherapy was associated with the absence or low 
expression of ERCC1 (test for interaction, P=0.009) with a 
significantly prolonged disease-free survival and OS among 
patients with ERCC1-negative tumors (HR for death, 
0.65; 95% CI, 0.50-0.86; P=0.002) as opposed to ERCC-1 
positive tumors. Morever, the prognostic value of ERCC1 
was confirmed in the control group with a significantly 
higher 5-year OS among patients with ERCC1-positive 
tumors than negative ones (HR, 0.66; 95% CI, 0.49-0.90; 
P=0.009). The same tumors were also scored by AQUA 
and low ERCC1 scores were marginally prognostic 
(HR =0.77 for high versus low scores, P=0.10) (23) while in 
an additional study, ERCC1 was exclusively predictive in 
squamous cell carcinoma (24).
The specificity of the commonly used mouse monoclonal 
antibody 8F1 to ERCC1 has been extensively debated 
(25,26). It was also found that none of the 16 antibodies 
tested could distinguish among the four known ERCC1 
protein isoforms (27). In the neo-adjuvant setting, mRNA 
ERCC1 levels in pretreatment tissue samples were 
correlated with the capacity to achieve an objective response 
following platinum-based chemotherapy (P<0.05), but not 
with the formation of local or distant metastases (28).
The predictive value of ERCC1 was enhanced by the 
concurrent evaluation of MutS homolog 2 (MSH2), a major 
active component of the mismatch repair system. Patients 
with double-negative tumors experienced a greater benefit 
from chemotherapy (29).
Overall these data indicate a prognostic role of ERCC1 
expression while its predictive role remains to be further 
assessed and additional validation studies are needed.
Breast cancer susceptibility gene 1
The protein encoded by breast cancer susceptibility gene 
1 (BRCA1) has a crucial role in DNA repair as well as in 
cell-cycle checkpoints and mitotic spindle assembly (30). 
BRCA1 sensitizes cancer cells to apoptosis induced by 
antimicrotubule drugs, such as taxanes and vinca alkaloids, 
while conferring resistance to DNA-damaging agents, 
including platinum agents. The potential prognostic role of 
a panel of nine candidate biomarkers including BRCA1 was 
investigated in two independent cohorts of chemotherapy 
naive patients with early-stage NSCLC. BRCA1 was the 
only independent factor affecting OS (31). In a group 
of patients with locally advanced NSCLC, treated with 
neo-adjuvant cisplatin and gemcitabine followed by surgery, 
those with the lowest levels of BRCA1 mRNA expression 
had significantly greater benefit from chemotherapy in 
terms of clinical and pathological downsizing and OS (32).
For its localization to sites of DNA double strand 
breaks, the upstream activity of the receptor-associated 
protein 80 (RAP-80) is required for BRCA1. In a first 
line study in advanced NSCLC patients with the lowest 
expression of both BRCA1 and RAP-80 receiving cisplatin 
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plus gemcitabine it was shown that RAP-80 can modulate 
the effect of BRCA1. In addition to a close correlation 
with BRCA1, RAP-80 expression was identified as an 
independent predictor for OS (33). In a phase II feasibility 
study of adjuvant chemotherapy in patients with stage II-
IIIA NSCLC, those with high BRCA1 transcriptional 
levels received single agent docetaxel, whereas those with 
intermediate and low BRCA1 expression were treated 
with cisplatin-doublets and OS did not differ between the 
treatment arms (34).
A recent meta-analysis of 23 studies assessed the role of 
BRCA1 as a predictor of clinical outcome in platinum- and 
paclitaxel-based chemotherapy in NSCLC patients. In 17 
platinum-based studies, low/negative BRCA1 was associated 
with better objective response rate [ORR] (OR =1.70, 95% 
CI, 1.32-2.18), longer OS and event-free survival [EFS] 
(HR =1.58, 95% CI, 1.27-1.97, and HR =1.60, 95% CI, 
1.07-2.39 for OS and EFS, respectively). In 4 paclitaxel-
based chemotherapy studies, patients with high/positive 
BRCA1 had better ORR (OR =0.41, 95% CI, 0.26-0.64) 
while OS and EFS were not evaluated because of the 
insufficient data available (35). Some studies reported that 
ERCC1 expression is closely linked to RRM1 and BRCA1 
levels (32,36,37), with concordant levels in 70-80% of cases 
(20,38).
Ribonucleotide reductase M1
Ribonucleotide reductase M1 (RRM1) is the regulatory 
component of  an essential  enzyme that catalyzes 
the reduct ion of  r ibonucleoside diphosphates  to 
the corresponding deoxyribonucleotides. A role for 
ribonucleotide reductase in DNA repair has been proposed, 
given the capacity of RRM1 to bind a p53-regulated paralog 
of RRM2 called p53R2 (39,40). Increased RRM1 predicts 
for decreased tumor invasiveness and metastatic potential, 
therefore predicting for more indolent behavior, perhaps 
mediated through its direct correlation with phosphatase 
and PTEN (phosphatase and tensin homolog) protein 
expression (41,42). In resected NSCLC, RRM1 protein 
proved prognostic, with low levels associated with a median 
OS of 60.2 months, compared to more than 120 months 
in high RRM1 tumors (43). RRM1 is a major predictor 
of disease response to gemcitabine, being its predominant 
target, as well as platinum (44). Several studies investigated 
the predictive value of RRM1 in patients treated with 
gemcitabine plus cisplatin (45,46) demonstrating that RRM1 
expression was significantly and inversely correlated with 
disease response, though not with survival (47). A recent 
meta-analysis in 1,243 patients with advanced NSCLC 
treated with gemcitabine-based regimens concluded that 
low tumor RRM1 was associated with a better response rate 
and longer survival (48). 
Thymidylate synthase
Thymidylate synthase (TS) catalyzes the conversion of 
deoxyuridine monophosphate (dUMP) to (deoxy) thymidine 
monophosphate (TMP), which requires oxidization of 
tetrahydrofolate to dihydrofolate. High tumoral levels of 
TS have been associated with resistance to 5-FU (49-51). 
Retrospective and prospective data from phase III trials 
in advanced NSCLC have established the favorable 
predictive value of TS in non-squamous NSCLC treated 
with pemetrexed with mRNA and protein TS expression 
lower in non-squamous compared to squamous histology 
and small cell lung cancer (52,53).These findings have been 
recently confirmed in a large retrospective study, although 
there was a wide range between individual patients (54).
Similarly distinct TS expression patterns among NSCLC 
subtypes were observed in stage I-IIIA NSCLC (55). In 
two different cohorts of chemotherapy naive patients with 
resected early-stage NSCLC, TS was a prognostic factor 
with mixed results. In one study high TS mRNA (but not 
protein) expression, was significantly associated with adverse 
disease free survival (DFS) and in the other study, high TS 
expression as determined by AQUA but not by qRT-PCR, 
predicted improved OS (55,56).
ITACA (International  TAilored Chemotherapy 
Adjuvant) (57) trial is a randomized phase III trial 
c o m p a r i n g  a d j u v a n t  p h a r m a c o g e n o m i c - d r i v e n 
chemotherapy based on ERCC-1 and TS assessment 
by qRT-PCR versus standard adjuvant chemotherapy 
in completely resected stage II-IIIA NSCLC. The 
molecular assessment groups patients into four different 
genetic profiles with patients dichotomized by high versus 
low expression of both ERCC-1 and TS. Within 30 to 
45 days post-surgery, patients in each genetic profile 
are randomized to receive either a standard adjuvant 
chemotherapy doublet (control arm) or an experimental 
treatment guided by molecular determinants (tailored 
chemotherapy arm). The study is currently accruing 
patients in Italy and in Germany and more than 600 
patients have been already randomized (see Figure 1).
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Figure 1 Study Design of The ITACA Adjuvant Trial. Randomization is performed according to each genetic profile. Cisplatin-doublet, 
investigator choice is the Control Arm of the study. Chemotherapy is either Vinorelbine 25-30 mg/m2 IV over 10 minutes, days 1 and 
8 & Cisplatin 75 mg/m2 IV over 60 minutes, day 1, immediately following Vinorelbine or Docetaxel 75 mg/m2 IV over 60 minutes, day 
1 & Cisplatin 75 mg/m2 IV over 60 minutes, day 1, immediately following Docetaxel or Gemcitabine 1,200 mg/m2 IV over 30 minutes, 
days 1 and 8 & Cisplatin 75 mg/m2 IV over 60 minutes day 1, immediately following gemcitabine. For the purpose of the final statistical 
analysis at the end of the study all controls will be grouped together in one single group (control group, blu boxes and line) and all tailored 
chemotherapies will be assembled together (experimental group, orange boxes and line).
Cyclin-dependent kinase inhibitor 1B
The cyclin-dependent kinase inhibitor 1B, p27Kip1, is a 
tumor-suppressor protein that induces cell-cycle arrest in 
phase G1. Despite its anti-proliferative properties, p27Kip1 
up-regulation leads to de novo resistance to platinum 
agents by allowing cancer cells to repair DNA damage 
and avoid apoptosis. A survival benefit from cisplatin-
based chemotherapy was only demonstrated in patients 
with p27Kip1 negative tumors (58,59). Cyclin D2 has been 
associated with poor recurrence-free survival in patients 
in stage III NSCLC treated with surgery with or without 
adjuvant chemotherapy (60).
β-tubulin
β-tubulin (βTubIII) is an essential element of microtubules, 
which serves as a cellular structural component involved 
in vital processes, including mitosis. Class IIIβ-tubulin 
(βTUBIII) corresponds to an isotype with enhancing 
impact on microtubule dynamics, contributing to intrinsic 
cancer cell resistance to antimitotic agents. Several 
studies have shown that βTubIII expression may predict 
response and outcome in patients with advanced NSCLC 
receiving tubulin binding agents (61,62). In patients with 
early stage NSCLC treated with an adjuvant vinorelbine-
based regimen (2), high βTUBIII expression was shown 
to be an independent adverse predictor of recurrence-free 
survival (63). The prognostic value was confirmed 
retrospectively in patients enrolled in another adjuvant 
study (64) and more recently in a neo-adjuvant study (65). 
In patients with β-tubulin positive immunostaining, median 
PFS was 30.6 versus 60.1 months (HR =1.46; 95% CI, 
1.08-1.99) for those negative.
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RAS oncogene and p53
KRAS mutation was associated in some studies with a poor 
prognosis in early NSCLC patients (66) but not in others. 
In the phase III NCIC JBR.10 adjuvant trial, where patients 
with stage IB-II disease were prospectively stratified by the 
presence of mutation in any of the RAS genes, the effect of 
RAS mutation status on the treatment outcome and prognosis 
was not significant. Nevertheless, the lack of benefit from 
the cisplatin/vinorelbine combination in patients with RAS 
mutations, in contrast to the total study population, may 
suggest a possible negative predictive role (67). Similarly, 
another adjuvant study in stage IB patients showed that, the 
presence KRAS mutations trended for an inferior survival of 
patients with tumors larger than 4 cm (68). Consistent data 
were reported in an Italian adjuvant study where in a subgroup 
of 227 patients the presence of K-RAS mutation, but not 
p53 and Ki67, in the univariate, but not in the multivariate 
analysis, was associated with shorter survival (69).
p53 nuclear immunoreactivity is considered a surrogate 
marker of TP53 gene mutations. However, the sensitivity 
and positive predictive value of p53 IHC expression 
for TP53 mutation status are estimated to be only 75% 
and 65%, respectively (70). A retrospective analysis of 
the phase III NCIC-JBR.10 adjuvant trial showed p53 
IHC overexpression to be an independent unfavorable 
prognostic factor among patients in the observation arm. 
In contrast to p53 expression, TP53 mutation status was 
neither prognostic for survival, nor predictive for efficacy of 
adjuvant chemotherapy (71). 
Gene expression signatures
Microarray technologies allow exploration of the prognostic 
significance of thousands of markers using high-throughput 
and computational approaches. To date, in lung cancer 
more than 30 studies have been reported (72) a large 
number showing that gene expression signature may stratify 
early stage NSCLC patients with different prognosis or 
survival outcome.
Although most of these signatures have been validated 
in one or more independent patient cohorts, microarray 
dataset overlaps between the genes sets have consistently 
been minimal. Thus there is a strong possibility that sample 
collection methods, processing protocols, single-institution 
subject cohorts, small sample sizes, and peculiarities 
of the different microarray platforms are contributing 
significantly to the results. To address these issues, a 
multi-institutional collaborative study was conducted to 
generate gene expression profiles from a large number of 
samples with a priori determined clinical features, useful to 
evaluate proposed prognostic models for potential clinical 
implementation. A large series of lung adenocarcinomas 
were tested for whether microarray measurements of gene 
expression either alone or combined with basic clinical 
covariates (stage, age, sex) can be used to predict overall 
survival in lung cancer subjects. Risk scores were produced 
substantially correlated with actual subject outcome, 
especially when clinical and molecular information are 
combined to build prognostic models for early stage lung 
cancer (73).
A malignancy-risk gene signature composed of several 
genes associated with proliferative activity has been 
successfully applied to predict breast cancer risk (74,75) and 
also tested for prognostic and predictive value in an early-
stage NSCLC patients. The malignancy-risk gene signature 
was tested using a large NSCLC microarray dataset from 
the Director’s Challenge Consortium (n=442) and two 
independent NSCLC microarray datasets (n=117 and 133 
datasets, respectively). The malignancy-risk gene signature 
was significantly associated with OS (P<0.001) in two 
independent datasets and also with adjuvant chemotherapy 
(P=0.02) (76). Xu et al. developed an empirical model which 
is not based on the knowledge of patients’ survival time for 
determining the lung cancer biomarker signature. It has 
been hypothesized that instead of an individual gene, two 
functionally imbalanced groups of genes (Yin and Yang) 
determine the fate of the tumor cells, which ultimately 
determines patient’s survival time. The Yin and Yang genes 
were selected by comparing expression data from normal 
lung and lung cancer tissue samples using both unsupervised 
clustering and pathways analyses. The model was tested 
in four independent lung cancer datasets and significantly 
stratified patients into high- and low-risk survival groups and 
predicted chemotherapy outcomes for stages II and III (77).
A 14-gene expression assay that uses quantitative PCR, 
runs on formalin-fixed paraffin-embedded tissue samples, 
and differentiates patients with heterogeneous statistical 
prognoses was developed in a cohort of 361 resected 
patients with non-squamous NSCLC and validated in 2 
different cohorts of 433 patients with resected stage I non-
squamous NSCLC and 1,006 patients with stage I-III non-
squamous NSCLC resected in several leading Chinese 
cancer centres. The signature significantly segregated 
patients in low-, intermediate- and high-risk patients with 
relevant differences in 5-year survival rate. Multivariate 
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analysis in both cohorts indicated that no standard clinical 
risk factors could account for, or provide, the prognostic 
information derived from tumour gene expression. This 
quantitative-PCR-based assay reliably identified patients 
with early-stage non-squamous NSCLC at high risk for 
mortality after surgical resection (78).
Other biomarkers in early NSCLC
Insulin receptor (IR) and Insulin-like growth factor receptor 
(IGF1R) are implicated in the development and progression 
of NSCLC, either by interacting with the EGFR pathway 
or independently. In patients with resected NSCLC, IGF1R 
amplification determined by FISH was an independent 
favorable prognostic factor, unlike IGF1R protein (79). 
It has been observed that in early stage NSCLC, IGF1R/
EGFR FISH+ and IGF1R/EGFR IHC+ were associated 
with shorter disease-free survival (P=0.05 and P=0.05, 
respectively). Patients with concomitant IGF1R/EGFR 
FISH+/IHC+ had a worse DFS and OS (P=0.005 and 
P=0.01, respectively) (80).
Hepatocyte growth factor receptor (c-MET) is a proto-
oncogene associated with tumor invasive growth. In patients 
with resected stage I-III carcinomas, not treated with 
adjuvant chemotherapy, a high MET gene copy number 
was an independent adverse prognostic factor mainly 
in squamous histotype (81). Similarly, in patients with 
early-stage NSCLC HER2 expression was associated with 
poorer prognosis especially in stages IB and IIA diseases (82).
Higher expression of CXCR7 is associated with 
metastatic progression and poor DFS in patients with stage 
I NSCLC (83). In a retrospective analysis of completely 
resected stage I tumors, patients with CXCR4-positive 
tumors had a significantly longer survival than patients 
with CXCR4-negative tumors (P=0.039). Interestingly, the 
5-year metastasis rates were 23.5% and 34.1% in patients 
with CXCR4-positive and CXCR4-negative expression, 
respectively (P=0.2) (84).
Recently, a set of genes with altered methylation 
status were identified in stage I NSCLCs, some of which 
associated with survival. Such newly identified potential 
candidates for a NSCLC molecular screening need further 
analysis in order to determine their clinical utility (85,86).
Studies in early stage NSCLC have reported an 
association between vascular endothelial growth factor 
(VEGF) over-expression and progression or poor survival 
(87,88), but overall the prognostic role of VEGF expression 
in NSCLC remains undetermined.
Conclusions
Currently, tumor stage remains the strongest predictor 
of survival in NSCLC. Early-stage patients are treated 
primarily by surgical resection. However, 30% to 55% of 
these patients develop recurrence and die of their disease. 
The current staging system is inadequate for predicting 
the outcome of treatment and the prognosis in individual 
patients. For this reason there is an urgent need to search 
for new individual biomarkers and gene signatures in 
the tumor tissue. Many studies have investigated several 
molecular alterations in early lung cancer and their 
predictive and prognostic implications are still a matter of 
clinical research and even for the most promising are not 
yet ready for prime time application. Currently, randomized 
clinical trials are exploring the real value of these new 
diagnostic tools.
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